163 related articles for article (PubMed ID: 38240681)
1. Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide.
DE Alcubierre D; Carretti AL; Ducray F; Jouanneau E; Raverot G; Ilie MD
Minerva Endocrinol (Torino); 2024 Jan; ():. PubMed ID: 38240681
[TBL] [Abstract][Full Text] [Related]
2. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
3. Emerging and Novel Treatments for Pituitary Tumors.
Ilie MD; Lasolle H; Raverot G
J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31349718
[TBL] [Abstract][Full Text] [Related]
4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
5. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
6. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Ilie MD; Vasiljevic A; Jouanneau E; Raverot G
Endocr Relat Cancer; 2022 May; 29(7):415-426. PubMed ID: 35521777
[TBL] [Abstract][Full Text] [Related]
8. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Ilie MD; Raverot G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
[TBL] [Abstract][Full Text] [Related]
9. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of the pituitary tumor microenvironment.
Ilie MD; De Alcubierre D; Carretti AL; Jouanneau E; Raverot G
Pharmacol Ther; 2023 Oct; 250():108506. PubMed ID: 37562699
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.
Jordan JT; Miller JJ; Cushing T; Seijo M; Batchelor TT; Arrillaga-Romany IC; Shih HA; Nachtigall LB; Loeffler JS; Dietrich J
Neurooncol Pract; 2018 Mar; 5(1):64-68. PubMed ID: 31385986
[TBL] [Abstract][Full Text] [Related]
13. Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.
Lin AL; Tabar V; Young RJ; Cohen M; Cuaron J; Yang TJ; Rosenblum M; Rudneva VA; Geer EB; Bodei L
J Endocr Soc; 2021 Oct; 5(10):bvab133. PubMed ID: 34466766
[TBL] [Abstract][Full Text] [Related]
14. Medical Therapy of Aggressive Pituitary Tumors.
Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Raverot G; Ilie MD
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101712. PubMed ID: 36274025
[TBL] [Abstract][Full Text] [Related]
16. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
17. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
[TBL] [Abstract][Full Text] [Related]
18. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G; Burman P; McCormack A; Heaney A; Petersenn S; Popovic V; Trouillas J; Dekkers OM;
Eur J Endocrinol; 2018 Jan; 178(1):G1-G24. PubMed ID: 29046323
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Duhamel C; Ilie MD; Salle H; Nassouri AS; Gaillard S; Deluche E; Assaker R; Mortier L; Cortet C; Raverot G
J Pers Med; 2020 Aug; 10(3):. PubMed ID: 32823651
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
